Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer

Current Opinion in Investigational Drugs

Volumn 9, Issue 10, 2008, Pages 1070-1077

  Sommer, P ^a   Ray, D W ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer; Dissociated compound; Glucocorticoid; Glucocorticoid receptor; Inflammation

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; AL 438; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LGD 5552; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; VASOPRESSIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CORTICOSTEROID METABOLISM; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OSTEOPOROSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; WEIGHT GAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; NEOPLASMS; RECEPTORS, GLUCOCORTICOID;

EID: 53049106594     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hench P: Effects of cortisone in the rheumatic diseases. Lancet (1950) 2(6634):483-484.
2. Stahn C, Löwenberg M, Hommes DW, Buttgereit F: Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol (2007) 275(1-2):71-78.
3. Schäcke H, Berger M, Rehwinkel H, Asadullah K: Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index. Mol Cell Endocrinol (2007) 275(1-2):109- 117.
4. Rhen T, Cidlowski JA: Anti-inflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med (2005) 353(16):1711-1723.
5. Rosen J, Miner JN: The search for safer glucocorticoid receptor ligands. Endocr Rev (2005) 26(3):452-464.
6. Herr I, Gassler N, Friess H, Büchler MW: Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis (2007) 12(2):271-291.
7. Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, Altevogt P, Bodenmüller W, Gassler N, Schnabel PA, Dienemann H et al: Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther (2007) 6(2):278-287.
8. Mattern J, Büchler MW, Herr I: Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther (2007) 6(9):1345-1354.
9. Dickmeis T, Lahiri K, Nica G, Vallone D, Santoriello C, Neumann CJ, Hammerschmidt M, Foulkes NS: Glucocorticoids play a key role in circadian cell cycle rhythms. PLoS Biol (2007) 5(4):e78.
10. Chrousos GP: Is 11β-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci USA (2004) 101(17):6329-6330.
11. Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR: Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci USA (2004) 101(44):15603-15608.
12. Meijer OC, Kalkhoven E, van der Laan S, Steenbergen PJ, Houtman SH, Dijkmans TF, Pearce D, de Kloet ER: Steroid receptor coactivator-1 splice variants differentially affect corticosteroid receptor signaling. Endocrinology (2005) 146(3):1438-1448.
13. Li G, Heaton JH, Gelehrter TD: Role of steroid receptor coactivators in glucocorticoid and transforming growth factor β regulation of plasminogen activator inhibitor gene expression. Mol Endocrinol (2006) 20(5):1025-1034.
14. Lu NZ, Collins JB, Grissom SF, Cidlowski JA: Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol Cell Biol (2007) 27(20):7143-7160.
15. Lu NZ, Cidlowski JA: Glucocorticoid receptor isoforms generate transcription specificity. Trends Cell Biol (2006) 16(6):301-307.
16. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM: Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med (2006) 203(1):7-13.
17. Hudson AR, Roach SL, Higuchi RI, Phillips DP, Bissonnette RP, Lamph WW, Yen J, Li Y, Adams ME, Valdez LJ, Vassar A et al: Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma. J Med Chem (2007) 50(19):4699-4709. • This is the first report of the anticancer activity of the GR ligand, AL-438.
18. Wintermantel TM, Berger S, Greiner EF, Schutz G: Evaluation of steroid receptor function by gene targeting in mice. J Steroid Biochem Mol Biol (2005) 93(2-5):107-112.
19. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schütz G: Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev (1995) 9(13):1608-1621.
20. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schütz G: DNA binding of the glucocorticoid receptor is not essential for survival. Cell (1998) 93(4):531-541.
21. Reichardt HM, Tuckermann JP, Göttlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schütz G: Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J (2001) 20(24):7168-7173.
22. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G: Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA (2000) 97(8):3919-3924.
23. Smit P, Russcher H, de Jong FH, Brinkmann AO, Lamberts SW, Koper JW: Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2. J Clin Endocrinol Metab (2005) 90(5):2994-3000.
24. Matthews L, Berry A, Ohanian V, Ohanian J, Garside H, Ray D: Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program. Mol Endocrinol (2008) 22(6):1320- 1330.
25. Limbourg FP, Liao JK: Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (2003) 81(3):168-174.
26. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE et al: Acute cardiovascular protective effects of corticosteroids are mediated by nontranscriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 8(5):473-479.
27. Boyle CD: Recent advances in the discovery of 11β-HSD1 inhibitors. Curr Opin Drug Discov Dev (2008) 11(4):495-511.
28. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR: 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA (2004) 101(17):6734-6739.
29. Perretti M, Paul-Clark MJ, Mancini L, Flower RJ: Generation of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: The nitrosteroids. Dig Liver Dis (2003) 35(Suppl 2):S41-S48.
30. Hyun E, Bolla M, Steinhoff M, Wallace JL, Soldato PD, Vergnolle N: Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX-1022, in a murine model of contact dermatitis. Br J Pharmacol (2004) 143(5):618-625.
31. Bodor N, Buchwald P: Corticosteroid design for the treatment of asthma: Structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des (2006) 12(25):3241-3260.
32. Teshima M, Fumoto S, Nishida K, Nakamura J, Ohyama K, Nakamura T, Ichikawa N, Nakashima M, Sasaki H: Prolonged blood concentration of prednisolone after intravenous injection of liposomal palmitoyl prednisolone. J Control Release (2006) 112(3):320-328.
33. Vayssière BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol (1997) 11(9):1245-1255.
34. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM et al: A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol (2003) 17(5):860-869.
35. Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol (2007) 264(1-2):164-170.
36. Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, Marschke K, Rosen J, Vajda E, Zhi L, Negro-Vilar A: Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA (2007) 104(49):19244-19249. • The in vitro, as well as in vivo, effects of a novel GR ligand are described, along with its side effect profile.
37. Lopez FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz MD, Marschke K, Rosen J, Rungta D, Viveros HO et al: LGD-5552, an anti-inflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology (2008) 149(5):2080-2089.
38. Ligand Pharmaceuticals Inc: Ligand Pharmaceuticals announces fourth quarter results. Press Release (2007): March 15.
39. Schäcke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA (2004) 101(1):227-232.
40. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G: A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA (2005) 102(44):15827-15832.
41. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Muller-Ladner U, Vander Cruyssen B, Verbruggen G, Haegeman G, Elewaut D: A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol (2008) 180(4):2608-2615.
42. Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr, Budunova I: Novel steroid receptor phytomodulator compound A inhibits growth and survival of prostate cancer cells. Cancer Res (2008) 68(12):4763-4773. • This is the first report of the anticancer activity of the GR ligand, compound A.
43. Wang JC, Shah N, Pantoja C, Meijsing SH, Ho JD, Scanlan TS, Yamamoto KR: Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity. Genes Dev (2006) 20(6):689-699. • The effect of conformational change in the GR after ligand binding is described in detail.
44. Thompson CF, Quraishi N, Ali A, Mosley RT, Tata JR, Hammond ML, Balkovec JM, Einstein M, Ge L, Harris G, Kelly TM et al: Novel glucocorticoids containing a 6,5-bicyclic core fused to a pyrazole ring: Synthesis, in vitro profile, molecular modeling studies, and in vivo experiments. Bioorg Med Chem Lett (2007) 17(12):3354-3361.
45. Barker M, Clackers M, Copley R, Demaine DA, Humphreys D, Inglis GG, Johnston MJ, Jones HT, Haase MV, House D, Loiseau R et al: Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J Med Chem (2006) 49(14):4216-4231.
46. Biggadike K, Boudjelal M, Clackers M, Coe DM, Demaine DA, Hardy GW, Humphreys D, Inglis GG, Johnston MJ, Jones HT, House D et al: Nonsteroidal glucocorticoid agonists: Tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/ transactivation) efficacy selectivity. J Med Chem (2007) 50(26):6519-6534.
47. Kuzmich D, Kirrane T, Proudfoot J, Bekkali Y, Zindell R, Beck L, Nelson R, Shih CK, Kukulka AJ, Paw Z, Reilly P et al: Identification of dissociated nonsteroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett (2007) 17(18):5025-5031.
48. Kroe RR, Baker MA, Brown MP, Farrow NA, Gautschi E, Hopkins JL, LaFrance RR, Kronkaitis A, Freeman D, Thomson D, Nabozny G et al: Agonist versus antagonist induce distinct thermodynamic modes of cofactor binding to the glucocorticoid receptor. Biophys Chem (2007) 128(2-3):156- 164.
49. Regan J, Lee TW, Zindell RM, Bekkali Y, Bentzien J, Gilmore T, Hammach A, Kirrane TM, Kukulka AJ, Kuzmich D, Nelson RM et al: Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonists. J Med Chem (2006) 49(26):7887-7896.
50. Zelent A, Petrie K, Boix-Chornet M, Melnick AM, Waxman S, Gore SD: Derepression in the desert: The third workshop on clinical translation of epigenetics in cancer therapeutics. Cancer Res (2008) 68(13):4967-4970.
51. Adcock IM: Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther (2001) 14(3):211-219.
52. Herr I, Pfitzenmaier J: Glucocorticoid use in prostate cancer and other solid tumours: Implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol (2006) 7(5):425-430.
53. Schacke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther (2002) 96(1):23-43.